Cargando…
Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
INTRODUCTION: This ongoing, prospective, open-label, non-comparative, multicenter phase IV study is evaluating the safety and efficacy of recombinant human growth hormone (rhGH; Omnitrope(®), Sandoz GmbH) in short children born small for gestational age (SGA). Here we report data from patients who h...
Autores principales: | Schwarz, Hans-Peter, Walczak, Mieczysław, Birkholz-Walerzak, Dorota, Szalecki, Mieczyslaw, Nanu, Michaela, Woehling, Heike, Schuck, Ellen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833801/ https://www.ncbi.nlm.nih.gov/pubmed/26886776 http://dx.doi.org/10.1007/s12325-016-0301-1 |
Ejemplares similares
-
One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
por: Schwarz, Hans-Peter, et al.
Publicado: (2014) -
Long-term follow up of carbohydrate metabolism and adverse events after termination of Omnitrope® treatment in children born small for gestational age
por: Walczak, Mieczyslaw, et al.
Publicado: (2021) -
Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data
por: Romer, Tomasz, et al.
Publicado: (2011) -
Correlation of Genotype and Perinatal Period, Time of Diagnosis and Anthropometric Data before Commencement of Recombinant Human Growth Hormone Treatment in Polish Patients with Prader–Willi Syndrome
por: Lecka-Ambroziak, Agnieszka, et al.
Publicado: (2021) -
Effects of Recombinant Human Growth Hormone Treatment, Depending on the Therapy Start in Different Nutritional Phases in Paediatric Patients with Prader–Willi Syndrome: A Polish Multicentre Study
por: Lecka-Ambroziak, Agnieszka, et al.
Publicado: (2021)